Exicure (XCUR) Interest Expenses (2016 - 2025)
Exicure's (XCUR) quarterly Interest Expenses came in at $109000.0 in Q4 2025, down 90.91% YoY from $1.2 million in Q4 2024, and up 200.0% on a QoQ basis from -$109000.0 in Q2 2025.
Exicure (XCUR) Interest Expenses (2016 - 2025) Analysis & Trends
Exicure (XCUR) has 10 years of Interest Expenses data on file, last reported at $109000.0 in Q4 2025.
- Quarterly Interest Expenses fell 90.91% year-over-year to $109000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $109000.0 (down 91.04% YoY) and the FY2025 annual result came in at $7.7 million, up 11.82% from the prior year.
- Interest Expenses grew to $109000.0 in Q4 2025, from -$109000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $1.3 million in Q2 2021 to a low of -$109000.0 in Q2 2025.
- A 5-year average of $402230.8 and a median of $109000.0 in 2025 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2021 — Interest Expenses soared 1585.19% — and 2025, when it sank 1916.67%.
- Tracing XCUR's Interest Expenses over 5 years: stood at -$30000.0 in 2021, then soared by 110.0% to $3000.0 in 2022, then surged by 21433.33% to $646000.0 in 2023, then surged by 85.6% to $1.2 million in 2024, then sank by 90.91% to $109000.0 in 2025.
- The last three Interest Expenses figures came in at $109000.0 (Q4 2025), -$109000.0 (Q2 2025), and $109000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Exicure | 7.27 Mn | 7.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 109,000.00 |
| Dec 31, 2025 | 109,000.00 |
| Jun 30, 2025 | -109,000.00 |
| Jun 30, 2025 | -109,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Dec 31, 2024 | 1.20 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 12,000.00 |
| Sep 30, 2024 | 12,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Mar 31, 2023 | 646,000.00 |
| Mar 31, 2023 | 646,000.00 |
| Jun 30, 2022 | 3,000.00 |
| Jun 30, 2022 | 3,000.00 |
| Mar 31, 2022 | 872,000.00 |
| Mar 31, 2022 | 872,000.00 |
| Dec 31, 2021 | -30,000.00 |
| Dec 31, 2021 | -30,000.00 |